Anti-IL13Ralpha2 CAR T-cells
Recurrent Astrocytoma, IDH-Mutant, Grade 4
City of Hope Medical CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Recurrent Astrocytoma, IDH-Mutant, Grade 4 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
Nivolumab Andrew P. Groves | Phase 2 | B |
Pembrolizumab Mayo Clinic | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
gi-102 Mayo Clinic | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
Anti-IL13Ralpha2 CAR T-cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →